-DOCSTART- -X- O
Zika -X- _ O
virus -X- _ O
( -X- _ O
ZIKV -X- _ O
) -X- _ O
infection -X- _ O
can -X- _ O
cause -X- _ O
severe -X- _ O
congenital -X- _ O
diseases -X- _ O
, -X- _ O
such -X- _ O
as -X- _ O
microcephaly -X- _ O
, -X- _ O
ocular -X- _ O
defects -X- _ O
and -X- _ O
arthrogryposis -X- _ O
in -X- _ O
fetuses -X- _ O
, -X- _ O
and -X- _ O
Guillain–Barré -X- _ O
syndrome -X- _ O
in -X- _ O
adults. -X- _ O
Efficacious -X- _ O
therapeutic -X- _ O
treatments -X- _ O
for -X- _ O
infected -X- _ O
patients -X- _ O
, -X- _ O
as -X- _ O
well -X- _ O
as -X- _ O
prophylactic -X- _ O
treatments -X- _ O
to -X- _ O
prevent -X- _ O
new -X- _ O
infections -X- _ O
are -X- _ O
needed -X- _ O
for -X- _ O
combating -X- _ O
ZIKV -X- _ O
infection. -X- _ O
Here -X- _ O
, -X- _ O
we -X- _ O
report -X- _ O
that -X- _ O
ZIKV-specific -X- _ B-Intervention
human -X- _ I-Intervention
polyclonal -X- _ I-Intervention
antibodies -X- _ I-Intervention
( -X- _ I-Intervention
SAB-155 -X- _ I-Intervention
) -X- _ I-Intervention
, -X- _ O
elicited -X- _ O
in -X- _ O
transchromosomal -X- _ O
bovine -X- _ O
( -X- _ O
TcB -X- _ O
) -X- _ O
, -X- _ O
provide -X- _ O
significant -X- _ O
protection -X- _ O
from -X- _ O
infection -X- _ O
by -X- _ O
ZIKV -X- _ O
in -X- _ O
STAT2 -X- _ B-Patient
knockout -X- _ I-Patient
( -X- _ I-Patient
KO -X- _ I-Patient
) -X- _ I-Patient
golden -X- _ I-Patient
Syrian -X- _ I-Patient
hamsters -X- _ I-Patient
both -X- _ O
prophylactically -X- _ O
and -X- _ O
therapeutically. -X- _ O
These -X- _ O
antibodies -X- _ B-Outcome
also -X- _ I-Outcome
prevent -X- _ I-Outcome
testicular -X- _ I-Outcome
lesions -X- _ I-Outcome
in -X- _ I-Outcome
this -X- _ I-Outcome
hamster -X- _ I-Outcome
model. -X- _ I-Outcome
Our -X- _ I-Outcome
data -X- _ I-Outcome
indicate -X- _ I-Outcome
that -X- _ I-Outcome
antibody-mediated -X- _ I-Outcome
immunotherapy -X- _ I-Outcome
is -X- _ I-Outcome
effective -X- _ I-Outcome
in -X- _ I-Outcome
treating -X- _ I-Outcome
ZIKV -X- _ I-Outcome
infection. -X- _ I-Outcome
Because -X- _ I-Outcome
suitable -X- _ I-Outcome
quantities -X- _ I-Outcome
of -X- _ I-Outcome
highly -X- _ I-Outcome
potent -X- _ I-Outcome
human -X- _ I-Outcome
polyclonal -X- _ I-Outcome
antibodies -X- _ I-Outcome
can -X- _ I-Outcome
be -X- _ I-Outcome
quickly -X- _ I-Outcome
produced -X- _ I-Outcome
from -X- _ I-Outcome
the -X- _ I-Outcome
TcB -X- _ I-Outcome
system -X- _ I-Outcome
against -X- _ I-Outcome
ZIKV -X- _ I-Outcome
and -X- _ I-Outcome
have -X- _ I-Outcome
demonstrated -X- _ I-Outcome
therapeutic -X- _ I-Outcome
efficacy -X- _ I-Outcome
in -X- _ I-Outcome
a -X- _ I-Outcome
small -X- _ I-Outcome
animal -X- _ I-Outcome
model -X- _ I-Outcome
, -X- _ I-Outcome
they -X- _ I-Outcome
have -X- _ I-Outcome
the -X- _ I-Outcome
potential -X- _ I-Outcome
as -X- _ I-Outcome
an -X- _ I-Outcome
effective -X- _ I-Outcome
countermeasure -X- _ I-Outcome
against -X- _ I-Outcome
ZIKV -X- _ I-Outcome
infection -X- _ I-Outcome
. -X- _ O

